loading page

Highly efficient production of diverse rare ginsenosides using combinatorial biotechnology
  • +9
  • Ling-gai Cao,
  • Hao Wu,
  • He Zhang,
  • Quan Zhao,
  • Xue Yin,
  • Dongran Zheng,
  • Chuanwang Li,
  • Min-jun Kim,
  • Pyol Kim,
  • Zheyong Xue,
  • Yu Wang,
  • Yuhua Li
Ling-gai Cao
Northeast Forestry University
Author Profile
Hao Wu
Northeast Forestry University
Author Profile
He Zhang
Northeast Forestry University
Author Profile
Quan Zhao
Northeast Forestry University
Author Profile
Xue Yin
Northeast Forestry University
Author Profile
Dongran Zheng
Northeast Forestry University
Author Profile
Chuanwang Li
Northeast Forestry University
Author Profile
Min-jun Kim
Northeast Forestry University
Author Profile
Pyol Kim
Northeast Forestry University
Author Profile
Zheyong Xue
Northeast Forestry University
Author Profile
Yu Wang
Northeast Forestry University
Author Profile
Yuhua Li
Northeast Forestry University
Author Profile

Abstract

The rare ginsenosides are recognized as the functionalized molecules after oral administration of Panax ginseng and its products. The sources of rare ginsenosides are extremely limited because of low ginsenoside contents in wild plants, hindering their application in functional foods and drugs. We developed an effective combinatorial biotechnology approach including tissue culture, immobilization, and hydrolyzation methods. Rh2 and nine other rare ginsenosides were produced by MeJA-induced culture of adventitious roots in a 10 L bioreactor associated with enzymatic hydrolysis using six β-glycosidases and their combination with yields ranging from 5.54-32.66 mg L-1. The yield of Rh2 was furthermore increased 7% by using immobilized BglPm and Bgp1 in optimized pH and temperature condition, with the highest yield reaching 51.17 mg L-1 (17.06% of PPD-type ginsenosides mixture). Our combinatorial biotechnology method provides a highly efficient approach to acquiring diverse rare ginsenosides, replacing direct extraction from Panax plants, and can also be used to supplement yeast cell factories.

Peer review status:ACCEPTED

05 Dec 2019Submitted to Biotechnology and Bioengineering
10 Dec 2019Submission Checks Completed
10 Dec 2019Assigned to Editor
16 Dec 2019Reviewer(s) Assigned
03 Feb 2020Review(s) Completed, Editorial Evaluation Pending
03 Feb 2020Editorial Decision: Revise Minor
25 Feb 20201st Revision Received
26 Feb 2020Submission Checks Completed
26 Feb 2020Assigned to Editor
05 Mar 2020Review(s) Completed, Editorial Evaluation Pending
05 Mar 2020Editorial Decision: Accept